AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news28 August 2012 | By European Pharmaceutical Review
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
news28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
news13 August 2012 | By AstraZeneca
NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval...
news9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
news30 July 2012 | By Bristol-Myers Squibb
Bristol-Myers Squibb and AstraZeneca announced the results of analyses...
news16 July 2012 | By AstraZeneca
AstraZeneca reported on the remuneration arrangements relating to David Brennan’s retirement...
news6 July 2012 | By Abbott
Groundbreaking partnership that aims to speed the discovery of essential new treatments...
news6 July 2012 | By AstraZeneca
AstraZeneca has completed the previously indicated sale of the assets of its subsidiary, Aptium Oncology...
news30 June 2012 | By AstraZeneca
Bristol-Myers Squibb to acquire Amylin...
news27 June 2012 | By AstraZeneca
AstraZeneca and Merck have agreed to amend certain provisions of the agreements relating to the companies’ arrangements in the US...
news22 June 2012 | By AstraZeneca
Zinforo receives positive CHMP opinion...
news20 June 2012 | By AstraZeneca
AstraZeneca has completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc...
news9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
news24 May 2012 | By AstraZeneca
New €224m funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing...
news14 May 2012 | By University of Dundee
The consortium includes six companies & will provide core support of £14.4 million...